PLoS ONE volume 9, issue 5, Pe98315 2014 DOI: 10.1371/journal.pone.0098315 View full text
|
|
Share
Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg

Abstract: The humanized anti-CD22 antibody, epratuzumab, has demonstrated therapeutic activity in clinical trials of lymphoma, leukemia and autoimmune diseases, treating currently over 1500 cases of non-Hodgkin lymphoma, acute lymphoblastic leukemias, Waldenström’s macroglobulinemia, Sjögren’s syndrome, and systemic lupus erythematosus. Because epratuzumab reduces on average only 35% of circulating B cells in patients, and has minimal antibody-dependent cellular cytotoxicity and negligible complement-dependent cytotoxic…

expand abstract